Phase 3, Open-label Study to Assess the Efficacy and Safety of a Single Lumbar Intrathecal Administration of MELPIDA in Individuals with Hereditary Spastic Paraplegia Type 50 (SPG50) Versus Matched Prospective Concurrent Controls.

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

February 28, 2032

Study Completion Date

June 1, 2032

Conditions

Hereditary Spastic Paraplegia Type 50

Interventions

GENETIC

MELPIDA

Gene Therapy agent